162 related articles for article (PubMed ID: 11118042)
1. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.
Taylor MT; Lawson KR; Ignatenko NA; Marek SE; Stringer DE; Skovan BA; Gerner EW
Cancer Res; 2000 Dec; 60(23):6607-10. PubMed ID: 11118042
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
[TBL] [Abstract][Full Text] [Related]
3. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.
Babbar N; Ignatenko NA; Casero RA; Gerner EW
J Biol Chem; 2003 Nov; 278(48):47762-75. PubMed ID: 14506281
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
8. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
9. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
Williams CS; Goldman AP; Sheng H; Morrow JD; DuBois RN
Neoplasia; 1999 Jun; 1(2):170-6. PubMed ID: 10933052
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
12. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells.
Di Popolo A; Memoli A; Apicella A; Tuccillo C; di Palma A; Ricchi P; Acquaviva AM; Zarrilli R
Oncogene; 2000 Nov; 19(48):5517-24. PubMed ID: 11114729
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Yip-Schneider MT; Barnard DS; Billings SD; Cheng L; Heilman DK; Lin A; Marshall SJ; Crowell PL; Marshall MS; Sweeney CJ
Carcinogenesis; 2000 Feb; 21(2):139-46. PubMed ID: 10657949
[TBL] [Abstract][Full Text] [Related]
14. Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis.
Bottone FG; Martinez JM; Collins JB; Afshari CA; Eling TE
J Biol Chem; 2003 Jul; 278(28):25790-801. PubMed ID: 12734198
[TBL] [Abstract][Full Text] [Related]
15. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Reddy BS; Rao CV; Seibert K
Cancer Res; 1996 Oct; 56(20):4566-9. PubMed ID: 8840961
[TBL] [Abstract][Full Text] [Related]
17. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
[TBL] [Abstract][Full Text] [Related]
19. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.
Tang X; Sun YJ; Half E; Kuo MT; Sinicrope F
Cancer Res; 2002 Sep; 62(17):4903-8. PubMed ID: 12208739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
